| |
Univariate
|
Multivariate
|
|---|
|
OR
|
95% CI
|
p
|
OR
|
95% CI
|
p
|
|---|
|
Age
|
1.06
|
1.02–1.1
|
0.003
|
1.05
|
1.01–1.1
|
0.023
|
|
Prior negative biopsy
|
0.62
|
0.32–1.19
|
0.149
| | | |
|
DRE
| | | | | | |
|
Negative
|
reference
| | | | | |
|
Positive
|
0.58
|
0.31–1.09
|
0.089
| | | |
|
PSA
|
1.04
|
1.00–1.08
|
0.055
|
1.03
|
0.99–1.06
|
0.111
|
|
PI-RADS
| | | | | | |
|
3
|
reference
| | | | | |
|
> 3
|
5.25
|
1.72–16.02
|
0.004
|
5.99
|
1.72–20.84
|
0.005
|
|
Number of total cores
|
1.03
|
0.98–1.09
|
0.276
| | | |
|
Biopsy route
| | | | | | |
|
Transperineal
|
1.99
|
1.09–3.63
|
0.026
|
2.55
|
1.32–4.95
|
0.006
|
|
Transrectal
|
Reference
| | | | | |
|
Target lesion location
| | | | | | |
|
Posterior
|
Reference
| | | | | |
|
Anterior
|
2.02
|
1.09–3.74
|
0.026
|
1.81
|
0.91–3.57
|
0.09
|
- CI: confidence interval; csPC: clinically significant prostate cancer; DRE: digital rectal exam; OR: odds ratio; PSA: prostate specific antigen; PI-RADS: Prostate Imaging Reporting & Data System
